When was British Biotech founded?
British Biotech was founded in 1986.
Where is British Biotech's headquarters?
British Biotech's headquarters is located at Watlington Road, Oxford.
What is British Biotech's latest funding round?
British Biotech's latest funding round is Merger.
Who are the investors of British Biotech?
Investors of British Biotech include Vernalis and Domain Associates.
Who are British Biotech's competitors?
Competitors of British Biotech include Intas Pharmaceuticals, Rigel Pharmaceuticals, Creative Biomolecules, Cylene Pharmaceuticals, Renovis and 11 more.
You May Also Like
Choice Research of Birmingham is a company that manages clinical development trials.
Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.
Diasome Pharmaceuticals develops hepatocyte directed vesicle technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes to improve disease management and quality of life. The company was founded in 2004 and is based in Cleveland, Ohio.
Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.
Lifepharms is researching natural products for medicinal and agricultural uses, including anticancer and pox virus medications.
Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.